{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T10:16:00Z","timestamp":1783937760195,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s40256-024-00635-7","type":"journal-article","created":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T17:02:31Z","timestamp":1711126951000},"page":"285-302","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of Intravenous Iron in Patients with Heart Failure with Reduced Ejection Fraction and Iron Deficiency: A Systematic Review and Meta-Analysis of Randomized Control Trials"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9945-3549","authenticated-orcid":false,"given":"Andrew","family":"Sephien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denisse Camille","family":"Dayto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tea","family":"Reljic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Prida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna M.","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Tavares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason N.","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambuj","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,22]]},"reference":[{"key":"635_CR1","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/ehf2.14177","volume":"10","author":"A Sindone","year":"2023","unstructured":"Sindone A, Doehner W, Comin-Colet J. Systematic review and meta-analysis of intravenous iron-carbohydrate complexes in HFrEF patients with iron deficiency. ESC Heart Fail. 2023;10:44\u201356.","journal-title":"ESC Heart Fail"},{"key":"635_CR2","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jchf.2018.07.015","volume":"7","author":"S von Haehling","year":"2019","unstructured":"von Haehling S, Ebner N, Evertz R, Ponikowski P, Anker SD. Iron deficiency in heart failure: an overview. JACC Heart Fail. 2019;7:36\u201346.","journal-title":"JACC Heart Fail"},{"key":"635_CR3","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.030099","volume":"138","author":"IS Anand","year":"2018","unstructured":"Anand IS, Gupta P. Anemia and iron deficiency in heart failure: current concepts and emerging therapies. Circulation. 2018;138:80\u201398.","journal-title":"Circulation"},{"key":"635_CR4","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.jacc.2017.12.027","volume":"71","author":"BML Rocha","year":"2018","unstructured":"Rocha BML, Cunha GJL, Menezes Falcao LF. The burden of iron deficiency in heart failure: therapeutic approach. J Am Coll Cardiol. 2018;71:782\u201393.","journal-title":"J Am Coll Cardiol"},{"key":"635_CR5","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1093\/eurheartj\/ehs224","volume":"34","author":"EA Jankowska","year":"2013","unstructured":"Jankowska EA, von Haehling S, Anker SD, Macdougall IC, Ponikowski P. Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur Heart J. 2013;34:816\u201329.","journal-title":"Eur Heart J"},{"issue":"575\u201382","key":"635_CR6","volume":"165","author":"IT Klip","year":"2013","unstructured":"Klip IT, Comin-Colet J, Voors AA, et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J. 2013;165(575\u201382): e3.","journal-title":"Am Heart J"},{"key":"635_CR7","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1007\/s00392-021-01837-8","volume":"110","author":"FJ Graham","year":"2021","unstructured":"Graham FJ, Pellicori P, Ford I, Petrie MC, Kalra PR, Cleland JGF. Intravenous iron for heart failure with evidence of iron deficiency: a meta-analysis of randomised trials. Clin Res Cardiol. 2021;110:1299\u2013307.","journal-title":"Clin Res Cardiol"},{"key":"635_CR8","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1001\/jama.2017.5427","volume":"317","author":"GD Lewis","year":"2017","unstructured":"Lewis GD, Malhotra R, Hernandez AF, et al. Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT HF randomized clinical trial. JAMA. 2017;317:1958\u201366.","journal-title":"JAMA"},{"key":"635_CR9","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","volume":"361","author":"SD Anker","year":"2009","unstructured":"Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361:2436\u201348.","journal-title":"N Engl J Med"},{"key":"635_CR10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/eurheartj\/ehr504","volume":"34","author":"J Comin-Colet","year":"2013","unstructured":"Comin-Colet J, Lainscak M, Dickstein K, et al. The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study. Eur Heart J. 2013;34:30\u20138.","journal-title":"Eur Heart J"},{"key":"635_CR11","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jacc.2007.09.036","volume":"51","author":"DO Okonko","year":"2008","unstructured":"Okonko DO, Grzeslo A, Witkowski T, et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol. 2008;51:103\u201312.","journal-title":"J Am Coll Cardiol"},{"key":"635_CR12","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","volume":"396","author":"P Ponikowski","year":"2020","unstructured":"Ponikowski P, Kirwan BA, Anker SD, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet. 2020;396:1895\u2013904.","journal-title":"Lancet"},{"key":"635_CR13","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1161\/CIRCULATIONAHA.117.027497","volume":"136","author":"DJ van Veldhuisen","year":"2017","unstructured":"van Veldhuisen DJ, Ponikowski P, van der Meer P, et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation. 2017;136:1374\u201383.","journal-title":"Circulation"},{"key":"635_CR14","first-page":"5168","volume":"28","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M, et al. Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;28:5168.","journal-title":"Eur Heart J"},{"key":"635_CR15","unstructured":"Kalra PR, Cleland JGF, Petrie MC, et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet. 2022."},{"key":"635_CR16","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1002\/ehf2.14310","volume":"10","author":"HM Salah","year":"2023","unstructured":"Salah HM, Savarese G, Rosano GMC, Ambrosy AP, Mentz RJ, Fudim M. Intravenous iron infusion in patients with heart failure: a systematic review and study-level meta-analysis. ESC Heart Fail. 2023;10:1473.","journal-title":"ESC Heart Fail"},{"key":"635_CR17","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/NEJMoa2304968","volume":"389","author":"RJ Mentz","year":"2023","unstructured":"Mentz RJ, Garg J, Rockhold FW, et al. Ferric carboxymaltose in heart failure with iron deficiency. N Engl J Med. 2023;389:975.","journal-title":"N Engl J Med"},{"key":"635_CR18","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","volume":"8","author":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P","year":"2010","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8:336\u201341.","journal-title":"Int J Surg"},{"key":"635_CR19","doi-asserted-by":"crossref","unstructured":"Cumpston M, Li T, Page MJ, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev 2019;(10):ED000142.","DOI":"10.1002\/14651858.ED000142"},{"key":"635_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343: d5928.","journal-title":"BMJ"},{"key":"635_CR21","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383\u201394.","journal-title":"J Clin Epidemiol"},{"key":"635_CR22","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1016\/j.ijcard.2013.04.181","volume":"168","author":"L Beck-da-Silva","year":"2013","unstructured":"Beck-da-Silva L, Piardi D, Soder S, et al. IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia. Int J Cardiol. 2013;168:3439\u201342.","journal-title":"Int J Cardiol"},{"key":"635_CR23","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1161\/CIRCULATIONAHA.118.038516","volume":"139","author":"G Charles-Edwards","year":"2019","unstructured":"Charles-Edwards G, Amaral N, Sleigh A, et al. Effect of iron isomaltoside on skeletal muscle energetics in patients with chronic heart failure and iron deficiency. Circulation. 2019;139:2386\u201398.","journal-title":"Circulation"},{"key":"635_CR24","doi-asserted-by":"publisher","first-page":"Fso467","DOI":"10.2144\/fsoa-2019-0156","volume":"6","author":"S Dhoot","year":"2020","unstructured":"Dhoot S, Mittal S, Singh SP, Patel V, Kasliwal RR, Mehta V. Effect of ferric-carboxy maltose on oxygen kinetics and functional status in heart failure patients with iron deficiency. Future Sci OA. 2020;6:Fso467.","journal-title":"Future Sci OA"},{"key":"635_CR25","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1093\/eurheartj\/ehab724.1053","volume":"42","author":"G Filippatos","year":"2021","unstructured":"Filippatos G, Ponikowski P, Farmakis D, et al. Efficacy of intravenous ferric carboxymaltose in patients with acute heart failure and iron deficiency with and without anaemia: a subgroup analysis of AFFIRM-AHF. Eur Heart J. 2021;42:1053.","journal-title":"Eur Heart J"},{"key":"635_CR26","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1093\/eurheartj\/ehab234","volume":"42","author":"EA Jankowska","year":"2021","unstructured":"Jankowska EA, Kirwan BA, Kosiborod M, et al. The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. Eur Heart J. 2021;42:3011\u201320.","journal-title":"Eur Heart J"},{"key":"635_CR27","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/eurheartj\/suz157","volume":"21","author":"M Karakas","year":"2019","unstructured":"Karakas M. Effect of ferric carboxymaltose on LVEF as assessed by cardiac MRI in patients with chronic heart failure and iron deficiency: a randomized, double-blinded, placebo-controlled, dual-center trial. Eur J Heart Fail. 2019;21:176.","journal-title":"Eur J Heart Fail"},{"key":"635_CR28","doi-asserted-by":"publisher","first-page":"4905","DOI":"10.1093\/eurheartj\/ehab411","volume":"42","author":"P Martens","year":"2021","unstructured":"Martens P, Dupont M, Dauw J, et al. The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapy-the IRON-CRT trial. Eur Heart J. 2021;42:4905\u201314.","journal-title":"Eur Heart J"},{"key":"635_CR29","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.014254","volume":"9","author":"J Nu\u00f1ez","year":"2020","unstructured":"Nu\u00f1ez J, Minana G, Cardells I, et al. Noninvasive imaging estimation of myocardial iron repletion following administration of intravenous iron: the myocardial-IRON trial. J Am Heart Assoc. 2020;9: e014254.","journal-title":"J Am Heart Assoc"},{"key":"635_CR30","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","volume":"36","author":"P Ponikowski","year":"2015","unstructured":"Ponikowski P, Van Veldhuisen DJ, Comin-Colet J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015;36:657\u201368.","journal-title":"Eur Heart J"},{"key":"635_CR31","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/j.jacc.2007.07.029","volume":"50","author":"JE Toblli","year":"2007","unstructured":"Toblli JE, Lombra\u00f1a A, Duarte P, Di Gennaro F. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol. 2007;50:1657\u201365.","journal-title":"J Am Coll Cardiol"},{"key":"635_CR32","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/eurheartj\/ehx493.P5825","volume":"38","author":"G Youssef","year":"2017","unstructured":"Youssef G, Kamal A, Diab R, Abdel HM. Intravenous iron therapy in acute decompensated heart failure patients with iron deficiency anaemia. Eur Heart J. 2017;38:1231.","journal-title":"Eur Heart J"},{"key":"635_CR33","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1093\/eurjhf\/hft099","volume":"15","author":"G Filippatos","year":"2013","unstructured":"Filippatos G, Farmakis D, Colet JC, et al. Intravenous ferric carboxymaltose in iron-Deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial. Eur J Heart Fail. 2013;15:1267\u201376.","journal-title":"Eur J Heart Fail"},{"key":"635_CR34","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.amjmed.2019.02.018","volume":"132","author":"X Zhou","year":"2019","unstructured":"Zhou X, Xu W, Xu Y, Qian Z. Iron supplementation improves cardiovascular outcomes in patients with heart failure. Am J Med. 2019;132:955\u201363.","journal-title":"Am J Med"},{"key":"635_CR35","doi-asserted-by":"publisher","first-page":"5077","DOI":"10.1093\/eurheartj\/ehad586","volume":"44","author":"P Ponikowski","year":"2023","unstructured":"Ponikowski P, Mentz RJ, Hernandez AF, et al. Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis. Eur Heart J. 2023;44:5077\u201391.","journal-title":"Eur Heart J"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-024-00635-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-024-00635-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-024-00635-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T16:27:14Z","timestamp":1711556834000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-024-00635-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["635"],"URL":"https:\/\/doi.org\/10.1007\/s40256-024-00635-7","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"11 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Andrew Sephien, Denisse Camille Dayto, Tea Reljic, Xavier Prida, Joanna M. Joly, Matthew Tavares, Jason N. Katz, and Ambuj Kumar declare they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"No external funding was used in the preparation of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"AS: Conceptualization, data curation, analysis, investigation, methodology, writing. DCD: Conceptualization, data curation, analysis, investigation, reviewing and editing. TR: Conceptualization, data curation, investigation, analysis, methodology, reviewing and editing. XP: Conceptualization, investigation, reviewing and editing. JMJ: Conceptualization, investigation, reviewing and editing. MT: Conceptualization, investigation, reviewing and editing. JNK. Conceptualization, investigation, reviewing and editing. AK. Conceptualization, analysis, investigation, methodology, supervision, reviewing and editing.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}